Infections After Orthotopic Liver Transplantation

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue 4, 2014, Pages 347-360

  Pedersen, Mark ^a   Seetharam, Anil ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Donor transmission; Infection; Liver transplantation; Prophylaxis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ATOVAQUONE; CALCINEURIN INHIBITOR; CASPOFUNGIN; CIDOFOVIR; CLINDAMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; FLUCONAZOLE; FLUCYTOSINE; FOSCARNET; GANCICLOVIR; HERPES ZOSTER IMMUNOGLOBULIN; ITRACONAZOLE; PENTAMIDINE ISETHIONATE; POSACONAZOLE; PREDNISONE; PRIMAQUINE; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRIMETHOPRIM; UNINDEXED DRUG; VALGANCICLOVIR; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL THERAPY; ASPERGILLOSIS; BACTERIAL INFECTION; CANDIDIASIS; CLINICAL FEATURE; CRYPTOCOCCAL MENINGITIS; CYTOMEGALOVIRUS INFECTION; DIFFERENTIAL DIAGNOSIS; DIMORPHIC FUNGAL INFECTION; DISEASE TRANSMISSION; GRAFT RECIPIENT; HEPATITIS E; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; INVASIVE PROCEDURE; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYCOBACTERIOSIS; MYCOSIS; OPPORTUNISTIC INFECTION; ORGAN DONOR; PATIENT CARE; PNEUMOCYSTOSIS; REVIEW; SYMPTOM; TUBERCULOSIS; VIRUS INFECTION;

EID: 84920841154     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.07.004     Document Type: Review

References (150)

1. Vera A., Contreras F., Guevara F. Incidence and risk factors for infections after liver transplant: single-center experience at the University Hospital Fundacion Santa Fe de Bogota, Colombia. Transpl Infect Dis 2011, 13:608-615.
2. Romero F.A., Razonable R.R. Infections in liver transplant recipients. World J Hepatol 2011, 3:83-92.
3. Fishman J.A. Infection in solid-organ transplant recipients. NEngl J Med 2007, 357:2601-2614.
4. Fishman J.A., Issa N.C. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010, 24:273-283.
5. Blair S., Kusne S. Bacterial, mycobacterial, and protozoal infections after liver transplantation-part I. Liver Transpl 2005, 12:1452-1459.
6. Fishman J.A. Infections in immunocompromised hosts and organ transplant recipients: essentials. Liver Transpl 2011, 17:S34-S37.
7. Sun H.Y., Cacciarelli T.V., Singh N. Identifying a targeted population at high risk for infections after liver transplantation in the MELD era. Clin Transplant 2011, 25:420-425.
8. Nafady-Hego H., Elgendy H., Moghazy W.E., Fukuda K., Uemoto S. Pattern of bacterial and fungal infections in the first 3 months after pediatric living donor liver transplantation: an 11-year single-center experience. Liver Transpl 2011, 17:976-984.
9. Van Hoek B., de Rooij B.J., Verspaget H.W. Risk factors for infection after liver transplantation. Best Pract Res Clin Gastroenterol 2012, 26(1):61-72.
10. Brown R.A., Gralewski J.H., Eid A.J., Knoll B.M., Finberg R.W., Razonable R.R. R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins. Transplantation 2010, 89:811-815.
11. Brown R.A., Gralewski J.H., Razonable R.R. The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus. Clin Infect Dis 2009, 49:e96-e99.
12. Eid A.J., Brown R.A., Paya C.V., Razonable R.R. Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 2007, 84:511-516.
13. Ren Y., Ding Q., Zhang X. Ficolins and infectious diseases. Virol Sin 2014, 29(1):25-32.
14. Cervera C., Balderramo D., Suarez B., et al. Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation. Liver Transpl 2009, 15:1217-1224.
15. Worthley D.L., Johnson D.F., Eisen D.P., et al. Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation. Clin Infect Dis 2009, 48:410-417.
16. Bouwman L.H., Roos A., Terpstra O.T., et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005, 129:408-414.
17. Cervera C., Linares L., Bou G., Moreno A. Multidrug-resistant bacterial infection in solid organ transplant recipients. Enferm Infecc Microbiol Clin 2012 Mar, 30(suppl 2):40-48.
18. Esfeh J.M., Hanouneh I.A., Koval C.E., et al. Impact of pretransplant rifaximin therapy on early post-liver transplant infections. Liver Transpl 2014 Feb 3, epub.
19. Benson A.B., Burton J.R., Austin G.L., et al. Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl 2011, 17:149-158.
20. Jafarian A., Kasraianfard A., Nassiri-Toosi M. Revision liver transplant for persistent infection and localized aspergillosis after hepatic artery thrombosis. Exp Clin Transplant 2014 Jan 13, [Epub ahead of print].
21. Leithead J.A., Smith M.R., Materacki L.B., et al. Intercurrent infection predicts mortality in patients with late hepatic artery thrombosis listed for liver retransplantation. Liver Transpl 2012, 18:1353-1360.
22. Poley J.W., Lekkerkerker M.N., Metselaar H.J., Kuipers E.J., Bruno M.J. Clinical outcome of progressive stenting in patients with anastomotic strictures after orthotopic liver transplantation. Endoscopy 2013, 45:567-570.
23. Avkan-Oguz V., Ozkardesler S., Unek T., et al. Risk factors for early bacterial infections in liver transplantation. Transplant Proc 2013, 45:993-997.
24. Sganga G., Bianco G., Fiori B., et al. Surveillance of bacterial and fungal infections in the postoperative period following liver transplantation: a series from 2005-2011. Transplant Proc 2013 Sep, 45(7):2718-2721.
25. Kawecki D., Pacholczyk M., Łagiewska B., et al. Urinary tract infections in the early posttransplant period after liver transplantation: etiologic agents and their susceptibility. Transplant Proc 2011 Oct, 43(8):3052-3054.
26. Mittal C., Hassan S., Arshad S., et al. Clostridium difficile infection in liver transplant recipients: a retrospective study of rates, risk factors and outcomes. Am J Transplant 2014 Jun 5, 10.1111/ajt.12798.
27. Ki H.K., Son J.S., Oh W.S., et al. Infectious complications after liver transplantation according to donor: comparison between orthotopic and living donor transplantation. Infect Chemother 2004, 36(3):139-147.
28. Saner F.H., Olde Damink S.W., Pavlakovic G., et al. Pulmonary and blood stream infections in adult living donor and cadaveric liver transplant patients. Transplantation 2008, 85(11):1564-1568.
29. Terrault N.A., Shiffman M.L., Lok A.S., et al. Outcomes in hepatitis C virus-infected recipients of living donor versus deceased donor liver transplantation. Liver Transpl 2007, 13(1):122-129.
30. Tunca M.Z., Yilmaz Akçay E., Moray G., Ozen O., Ozdemir B.H. Acase of cerebral tuberculosis after liver transplant and literature review. Exp Clin Transplant 2014, 12(suppl 1):117-119.
31. Sun H.Y., Munoz P., Torre-Cisneros J., et al. Tuberculosis in solid-organ transplant recipients: disease characteristics and outcomes in the current era. Prog Transplant 2014, 24:37-43.
32. Graham J.C., Kearns A.M., Magee J.G., et al. Tuberculosis transmitted through transplantation. JInfect 2001, 43:251-254.
33. Bodro M., Sabé N., Santín M., et al. Clinical features and outcomes of tuberculosis in solid organ transplant recipients. Transplant Proc 2012 Nov, 44:2686-2689.
34. Holty J.E., Gould M.K., Meinke L., Keeffe E.B., Ruoss S.J. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009 Aug, 15(8):894-906.
35. Rasheed S., Zinicola R., Watson D., Bajwa A., McDonald P.J. Intra-abdominal and gastrointestinal tuberculosis. Colorectal Dis 2007, 9:773-783.
36. Singh N., Paterson D.L. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998, 27:1266-1277.
37. Ladds E. Disseminated tuberculosis following liver transplant presenting with an axillary abscess. BMJ Case Rep 2014 Feb 7, [Epub 2/2014]. http://dx.doi.org/10.1136/bcr-2013-202903.
38. Fábrega E., Sampedro B., Cabezas J., et al. Chemoprophylaxis with isoniazid in liver transplant recipients. Liver Transpl 2012, 18:1110-1117.
39. Aguado J.M., Torre-Cisneros J., Fortun J., et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009, 48:1276-1284.
40. Ahmadinejad Z., Ardalan F.A., Razzaqi M., Davoudi S., Jafarian A. QuantiFERON-TB Gold in Tube test for diagnosis of latent tuberculosis (TB) in solid organ transplant candidates: a single-center study in an area endemic for TB. Transpl Infect Dis 2013, 15(1):90-95.
41. Doucette K., Fishman J.A. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004, 38:1428-1439.
42. Longworth S.A., Vinnard C., Lee I., Sims K.D., Barton T.D., Blumberg E.A. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. Transpl Infect Dis 2014, 16:76-83.
43. Shi S.H., Lu A.W., Shen Y., et al. Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation. Chin Med J (Engl) 2008, 121:625-630.
44. Husain S., Tollemar J., Dominguez E.A., et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003, 75:2023-2029.
45. Kusne S., Tobin D., Pasculle A.W., Van Thiel D.H., Ho M., Starzl T.E. Candida carriage in the alimentary tract of liver transplant candidates. Transplantation 1994, 57:398-402.
46. Kusne S., Blair J. Viral and fungal infections after liver transplantation - part II. Liver Transpl 2006, 12:2-11.
47. Patel R., Portela D., Badley A.D., et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996, 62:926-934.
48. Paya C.V. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin Infect Dis 2001, 33:S47-S52.
49. Badley A.D., Seaberg E.C., Porayko M.K., et al. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 1997, 64:66-73.
50. Eschenauer G.A., Lam S.W., Carver P.L. Antifungal prophylaxis in liver transplant recipients. Liver Transpl 2009, 15:842-858.
51. Cruciani M., Mengoli C., Malena M., Bosco O., Serpelloni G., Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006, 12:850-858.
52. Singh N., Wagener M.M., Cacciarelli T.V., Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008, 8:426-431.
53. Liu X., Ling Z., Li L., Ruan B. Invasive fungal infections in liver transplantation. Int J Infect Dis 2011, 15:e298-e304.
54. Trudeau R.E.1, Bowman L.J., Wills A.R., Crippin J.S., Chapman W.C., Anderson C. Once weekly fluconazole for antifungal prophylaxis post-liver transplantation. HPB (Oxford) 2013, 15:541-547.
55. Saliba F., Delvart V., Ichaï P., et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. Clin Transplant 2013, 27:E454-E461.
56. Hoyo I., Sanclemente G., Cervera C., et al. Opportunistic pulmonary infections in solid organ transplant recipients. Transplant Proc 2012, 44:2673-2675.
57. Kusne S., Torre-Cisneros J., Manez R., et al. Factors associated with invasive lung aspergillosis and the significance of positive aspergillus culture after liver transplantation. JInfect Dis 1992, 166:1379-1383.
58. Park Y.S., Seo J.B., Lee Y.K., et al. Radiological and clinical findings of pulmonary aspergillosis following solid organ transplant. Clin Radiol 2008, 63(6):673-680.
59. Munoz P., Guinea J., Bouza E. Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect 2006, 12:24-39.
60. Maertens J., Van Eldere J., Verhaegen J., Verbeken E., Verschakelen J., Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. JInfect Dis 2002, 186:1297-1306.
61. Mennink-Kersten M.A., Donnelly J.P., Verweij P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004, 4:349-357.
62. Latge J.P., Moutaouakil M., Debeaupuis J.P., Bouchara J.P., Haynes K., Prevost M.C. The 18-kilodalton antigen secreted by Aspergillus fumigatus. Infect Immun 1991, 59:2586-2594.
63. Pazos C., Ponton J., Del Palacio A. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. JClin Microbiol 2005, 43:299-305.
64. Singh N., Arnow P.M., Bonham A., et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997, 64:716-720.
65. Osawa M., Ito Y., Hirai T., et al. Risk factors for invasive aspergillosis in living donor liver transplant recipients. Liver Transpl 2007, 13:566-570.
66. Fortún J., Martín-Dávila P., Moreno S., et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002, 8:1065-1070.
67. Gavalda J., Len O., San Juan R., et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005, 41:52-59.
68. Pacholczyk M., Lagiewska B., Lisik W., Wasiak D., Chmura A. Invasive fungal infections following liver transplantation - risk factors, incidence and outcome. Ann Transplant 2011, 16:14-16.
69. Grossi P.A. Clinical aspects of invasive candidiasis in solid organ transplant recipients. Drugs 2009, 69(suppl 1):15-20.
70. Vilchez R., Shapiro R., McCurry K., et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int 2003, 16:336-340.
71. Chang C.M., Tsai C.C., Tseng C.E., et al. Donor-derived Cryptococcus infection in liver transplant: case report and literature review. Exp Clin Transplant 2014, 12:74-77.
72. Wu G., Vilchez R.A., Eidelman B., Fung J., Kormos R., Kusne S. Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis 2002, 4:183-188.
73. Perfect J.R., Dismukes W.E., Dromer F., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010, 50:291-322.
74. Assi M., Martin S., Wheat L.J., et al. Histoplasmosis after solid organ transplant. Clin Infect Dis 2013, 57:1542-1549.
75. Cuellar-Rodriguez J., Avery R.K., Lard M., et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplantcenter in an endemic area. Clin Infect Dis 2009, 49:710-716.
76. Vucicevic D.1, Carey E.J., Blair J.E. Coccidioidomycosis in liver transplant recipients in an endemic area. Am J Transplant 2011, 11:111-119.
77. Getrikkos G., Skiada A., et al. Epidemiology and clinical manifestations of mucormycosis. JInfect Dis 2012, 54(S1):S23-S34.
78. Singh N., Aguado J.M., Bonatti H., et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. JInfect Dis 2009, 200:1002-1011.
79. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for diagnosis and management of skin and soft-tissue infections. JInfect Dis 2005, 41:1373-1406.
80. Spellberg B., Ibrahim A.S. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep 2010, 12:423-429.
81. Wang E.H., Partovi N., Levy R.D., Shapiro R.J., Yoshida E.M., Greanya E.D. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis 2012, 14:519-525.
82. Reid A.B., Chen S.C., Worth L.J. Pneumocystis jiroveci pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 2011, 24:534-544.
83. Martin S.I., Fishman J.A. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009, 9:S227-S233. AST Infectious Diseases Community of Practice.
84. Patel G., Huprikar S. Infectious complications after orthotopic liver transplantation. Semin Respir Crit Care Med 2012, 33(1):111-124.
85. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094.
86. Lautenschlager I. CMV infection, diagnosis and antiviral strategies after liver transplantation. Transpl Int 2009, 22:1031-1040.
87. Razonable R.R. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008, 14:4849-4860.
88. Humar A., Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009, 9:S78-S86. AST Infectious Diseases Community of Practice.
89. Kotton C.N., Kumar D., Caliendo A.M., et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89:779-795. Transplantation Society International CMV Consensus Group.
90. Wadhawan M., Gupta S., Goyal N., et al. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience. Liver Transpl 2012, 18:1448-1455.
91. Razonable R.R. Cytomegalovirus infection after liver transplantation. Liver Transpl 2010, 16:S45-S55.
92. Paya C.V., Razonable R.R. Cytomegalovirus infection after solid organ transplantation. Transplant Infections 2003, 298-325. Lippincott, Williams and Wilkins, Philadelphia. R.A. Bowden, P. Ljungman, C.V. Paya (Eds.).
93. Rubin R.H. The direct and indirect effects of infection in liver transplantation: pathogenesis, impact and clinical management. Curr Clin Top Infect Dis 2002, 22:125.
94. Singh N., Wannstedt C., Keyes L., Wagener M.M., Gayowski T., Cacciarelli T.V. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005, 79:1428.
95. Burak K.W., Kremers W.K., Batts K.P., et al. Impact of cytomegalovirus infection, year of transplantation, and donorage on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002, 8:362.
96. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012, 26:531-548.
97. Mendez J.C., Dockrell D.H., Espy M.J. Human beta-herpesvirus interactions in solid organ transplant recipients. JInfect Dis 2001, 183:179.
98. Lautenschlager I., Lappalainen M., Linnavuori K., Suni J., Hockerstedt K. CMV infection is usually associated with concurrent HHV-6 and HHV-7 antigenemia in liver transplant patients. JClin Virol 2002, 25:57.
99. Manez R., Breinig M.C., Linden P., et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. JInfect Dis 1997, 176:1462-1467.
100. Lautenschlager I., Hockerstedt K., Jalanko H., et al. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997, 25:190.
101. Evans P.C., Coleman N., Wreghitt T.G., et al. Cytomegalovirus infection of bile duct epithelial cells, hepatic artery and portal venous endothelium in relation to chronic rejection of the liver grafts. JHepatol 1999, 31:913.
102. Roman A., Manito N., Campistol J.M., et al. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev (Orlando) 2014, 28:84-89.
103. Steinhoff G., Behrend M., Schrader B., Pichlmayr R. Intercellular immune adhesion molecules in human liver transplants: overview on expression patterns of leukocyte receptor and ligand molecules. Hepatology 1993, 18:440.
104. Martelius T., Krogerus L., Hockerstedt K., et al. Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology 1998, 27:996.
105. Martelius T., Salmi M., Wu H., et al. Inductions of vascular adhesion protein-1 (VAP-1) during liver allograft rejection and concomitant CMV infection in rats. Am J Pathol 2000, 157:1229.
106. Arnold J.C., Portman B.C., O'Grady J.G., Naoumov N.V., Alexander G.J.M., Williams R. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992, 16:285.
107. Gao L.H., Zheng S.S. Cytomegalovirus and chronic allograft rejection in liver transplantation. World J Gastroenterol 2004, 10:1857-1861.
108. Rubin R.H. Preemptive therapy in immunocompromised hosts. NEngl J Med 1991, 324:1057-1059.
109. Griffiths P., Whitley R., Snydman D.R., Singh N., Boeckh M. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop 2007. Herpes 2008, 15:4.
110. Levitsky J., Singh N., Wagener M.M., Stosor V., Abecassis M., Ison M.G. CMV survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008, 8:158.
111. Eid A.J., Arthus S.K., Deziel S.K., Wilhelm M.P., Razonable R.R. Emerge of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008, 22:162.
112. Limaye A.P., Bakthatsalam R., Kim H.W., et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004, 78:1390.
113. Limaye A.P., Bakthavatsalam R., Kim H.W., et al. Impact of cytomegalovirus in organ transplant recipient in the era of antiviral prophylaxis. Transplantation 2006, 8:1645-1655.
114. Asberg A., Humar A., Rollag H., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007, 7:2106-2113. VICTOR Study Group.
115. Allen U., Preiksaitis J. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009, 9:S87-S96. AST Infectious Diseases Community of Practice.
116. Kamdar K.Y., Rooney C.M., Heslop H.E. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant 2011, 16:274-280.
117. Burra P., Buda A., Livi U., et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?. Eur J Gastroenterol Hepatol 2006, 18:1065-1070.
118. Jain A., Nalesnik M., Reyes J., et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002, 236:429-436.
119. Kremers W.K., Devarbhavi H.C., Wiesner R.H., Krom R.A., Macon W.R., Habermann T.M. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006, 6(pt 1):1017-1024.
120. Koch D.G., Christiansen L., Lazarchick J., Stuart R., Willner I.R., Reuben A. Posttransplantation lymphoproliferative disorder-the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007, 13:904-912.
121. Dhillon M.S., Rai J.K., Gunson B.K., Olliff S., Olliff J. Post-transplant lymphoproliferative disease in liver transplantation. Br J Radiol 2007, 80:337-346.
122. Dufour J.F., Fey M.F. What is the current treatment of PTLD after liver transplantation?. JHepatol 2006, 44:23-26.
123. Montalbano M., Slapak-Green G.I., Neff G.W. Fulminant hepatic failure from herpes simplex virus: post liver transplantation acyclovir therapy and literature review. Transplant Proc 2005, 37:4393-4396.
124. Lucey M.R., Terrault N., Ojo L., Hay, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013, 19:3-26.
125. Razonable R.R., Rivero A., Brown R.A., et al. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003, 17:114-120.
126. Razonable R.R., Paya C.V. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002, 8:651-658.
127. Lautenschlager I., Linnavuori K., Hockerstedt K. Human herpesvirus-6 antigenemia after liver transplantation. Transplantation 2000, 69:2561-2566.
128. Lautenschlager I., Razonable R.R. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transpl Int 2012 May, 25(5):493-502.
129. Rogers J., Rohal S., Carrigan D.R., et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000, 69:2566-2573.
130. Benhammane H., Mentha G., Tschanz E., El Mesbahi O., Dietrich P.Y. Visceral Kaposi's sarcoma related to human herpesvirus-8 in liver transplant recipient: case report and literature review. Case Rep Oncol Med 2012, 137291.
131. Pozo F., Tenorio A., de la Mata M., de Ory F., Torre-Cisneros J. Persistent human herpesvirus 8 viremia before Kaposi's sarcoma development in a liver transplant recipient. Transplantation 2000, 70:395-397.
132. Lebbe C., Porcher R., Marcelin A.G., et al. Human herpesvirus 8 (HHV8) transmission and related morbidity in organ recipients. Am J Transplant 2013 Jan, 13(1):207-213.
133. Jenkins F.J., Hoffman L.J., Liegey-Dougall A. Reactivation of and primary infection with human herpesvirus 8 among solid-organ transplant recipients. JInfect Dis 2002, 185:1238-1243.
134. Ruocco E., Ruocco V., Tornesello M.L., Gambardella A., Wolf R., Buonaguro F.M. Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol 2013, 31:413-422.
135. Nelson K.E., Kmush B., Labrique A.B. The epidemiology of hepatitis E virus infections in developed countries and among immunocompromised patients. Expert Rev Anti Infect Ther 2011, 9:1133-1148.
136. Haagsma E.B., van den Berg A.P., Porte R.J., et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008, 14:547-553.
137. Kamar N., Selves J., Mansuy J.M., et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. NEngl J Med 2008, 358:811-817.
138. Pischke S., Suneetha P.V., Baechlein C., et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010, 16:74-82.
139. Te H.S., Drobeniuc J., Kamili S., Dong C., Hart J., Sharapov U.M. Hepatitis E virus infection in a liver transplant recipient in the United States: a case report. Transplant Proc 2013, 45:810-813.
140. Kamar N., Izopet J., Tripon S., et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. NEngl J Med 2014 Mar 20, 370:1111-1120.
141. Skagen C.L., Jou J.H., Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis. Clin Transplant 2011, 25(3):E243-E249.
142. Avelino-Silva V., D'Albuquerque L., Bonazzi P., et al. Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. Clin Transplant 2010, 24(6):735-746.
143. Ison M.G., Hager J., Blumberg E., et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009, 9:1929-1935.
144. Greenwald M.A., Kuehnert M.J., Fishman J.A. Infectious disease transmission during organ and tissue transplantation. Emerg Infect Dis Aug 2012, 18(8):e1. 10.3201/eid1808.120277.
145. Iwamoto M., Jernigan D.B., Guasch A., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. NEngl J Med 2003, 348:2196-2203.
146. Centers for Disease Control and Prevention West Nile virus infections in organ transplant recipients-New York and Pennsylvania, August-September, 2005. MMWR Morb Mortal Wkly Rep 2005, 54:1021-1023.
147. Centers for Disease Control and Prevention West Nile virus transmission via organ transplantation and blood transfusion-Louisiana, 2008. MMWR Morb Mortal Wkly Rep 2009, 58:1263-1267.
148. Fishman J.A., Greenwald M.A., Grossi P.A. Transmission of infection with human allografts: essential considerations in donor screening. Clin Infect Dis 2012 Sep, 55(5):720-727.
149. Pruett T.L., Blumberg E.A., Cohen D.J., et al. Aconsolidated biovigilance system for blood, tissue and organs: one size does not fit all. Am J Transplant 2012, 12(5):1099-1101.
150. Parikh N.D., Levitsky J. Hepatotoxicity and drug interactions in liver transplant candidates and recipients. Clin Liver Dis 2013, 17(4):737-747. x-xi.